You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)RET抑制劑產品「睿妥」正式商業化上市
信達生物(01801.HK)公布,由禮來製藥(LLY.US)研發、公司負責中國商業化的口服RET酪氨酸激(酉每)抑制劑產品「睿妥」(塞普替尼),已於近日在中國正式商業化上市,自3月4日起向全國供藥,可用於治療RET融合陽性的非小細胞肺癌、RET融合陽性的甲狀腺癌、RET突變型甲狀腺髓樣癌等病症。 信達生物製藥集團總裁劉勇軍表示,塞普替尼是全球首款獲批的高選擇性RET抑製劑,很高興見到其在臨床研究中展現出的顯著且持久的抗腫瘤活性及可耐受的安全性,今次在中國正式商業化上市是又一里程碑,將為國內RET融合及突變陽性癌症患者帶來國際品質的新治療選擇,未來將與禮來合作加快產品上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account